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Abstract
Amyloid peptide (Ah) is a 40/42-residue proteolytic fragment of a precursor protein (APP), implicated in the pathogenesis of Alzheimer’s
disease. The hypothesis that interactions between Ah aggregates and neuronal membranes play an important role in toxicity has gained some
acceptance. Previously, we showed that the C-terminal domain (e.g. amino acids 29–42) of Ah induces membrane permeabilisation and
fusion, an effect which is related to the appearance of non-bilayer structures. Conformational studies showed that this peptide has properties
similar to those of the fusion peptide of viral proteins i.e. a tilted penetration into membranes. Since piracetam interacts with lipids and has
beneficial effects on several symptoms of Alzheimer’s disease, we investigated in model membranes the ability of piracetam to hinder the
destabilising effect of the Ah 29–42 peptide. Using fluorescence studies and 31P and 2H NMR spectroscopy, we have shown that piracetam
was able to significantly decrease the fusogenic and destabilising effect of Ah 29–42, in a concentration-dependent manner. While the
peptide induced lipid disorganisation and subsequent negative curvature at the membrane–water interface, the conformational analysis
showed that piracetam, when preincubated with lipids, coats the phospholipid headgroups. Calculations suggest that this prevents appearance
of the peptide-induced curvature. In addition, insertion of molecules with an inverted cone shape, like piracetam, into the outer membrane
leaflet should make the formation of such structures energetically less favourable and therefore decrease the likelihood of membrane fusion.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Alzheimer’s disease is a progressive degenerative disease
of the brain characterized by loss of cognitive function
(dementia), selective neuronal death and abnormal forma-
tion in the brain of neuritic amyloid plaques. Genetic,
neuropathologic, transgenic and modelling studies implicate
the accumulation of h-amyloid peptides (Ah) as an impor-
tant step in the pathogenesis of the disease [1,2]. Ah is a 40/
42-residue proteolytic fragment of amyloid precursor pro-
tein (APP), an ubiquitous transmembrane protein [3]. Under
pathological conditions, Ah polymerises into extended h-
sheet structures that result in Ah fibrils characteristic of the
amyloid plaque.
The mechanism leading to Ah toxicity has been exten-
sively debated [4,5]. The hypothesis that interactions be-
tween Ah aggregates and neuronal membranes play an
important role in toxicity is now generally accepted [6]. In
vivo studies have shown that Ah proteins aggregate in a
membrane-bound conformation in dog and human brain
sections [7,8] and induce free-radical oxidative stress of
neuronal lipids in brain of Alzheimer patients [9]. In
cellular models, Ah has been reported to alter intramem-
branous structures [10], to increase permeability in lysoso-
mal and endosomal vesicles [11], to induce the formation
of cation-permeable channels [12] and to enhance the
activity of phospholipases A2, C and D [13–16]. In
addition to these in vivo and cellular observations, numer-
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ous studies have been performed using models of mem-
brane to characterise at the molecular level the binding of
Ah fragments to lipids [17–19], and the effects of this
interaction on the biophysical properties of the membrane.
In this respect, Ah peptides induce liposome fusion [20],
leakage of encapsulated dyes [17], formation of ion-chan-
nels [21,22] and perturbations in membrane fluidity [23–
27].
Focusing on membrane destabilisation and on the C-
terminal domain of Ah (residues 29–40 and 29–42) which
is critical for amyloid aggregation and fibril stabilisation
[28,29], Brasseur [30] has related membrane destabilisation
to the ability of the Ah C-terminal fragment to penetrate into
membranes with a 30–60j tilt with respect to the plane of
the lipid/water interface.
A number of approaches have been investigated to
improve the daily living activities of patients presenting
Alzheimer’s disease. For example, Ginkgo biloba, tacrine,
donezepil (acetylcholinesterase inhibitors), nimodipine (cal-
cium channel blocker) and piracetam (nootropic agent) have
been approved for the treatment of demented patients in
some European countries [31]. Clinical insights into noo-
troopic agents have shown that (i) long-term and high dose
treatment with piracetam may slow down the progression of
several clinical features of Alzheimer’s disease [32], (ii)
they have a comparable efficacy to acetylcholinesterase
inhibitors [33] and (iii) the cognitive relapse after discontin-
uation of the drug therapy is less pronounced compared to
cholinesterases inhibitors [34]. However, the molecular
mechanism of piracetam’s beneficial effects in Alzheimer’s
disease is not yet understood. Since results from the liter-
ature suggest that piracetam interacts with lipids [24], we
have investigated in model membrane systems the ability of
piracetam to hinder the membrane destabilising effect of the
Ah 29–42 synthetic peptide.
2. Materials and methods
2.1. Preparation of small unilamellar vesicles (SUV
liposomes)
These studies were performed on SUV, made of phos-
phatidylcholine (PC)/phosphatidylethanolamine (PE)/phos-
phatidylinositol (PI)/phosphatidylserine (PS)/sphingomyelin
(SM)/cholesterol (Chol) (30%:30%:2.5%:10%:5%:22.5%)
to mimic to some extent the composition of the neuronal
membrane [35].
A dry lipid film was obtained by evaporation of the
solvents of lipids (CHCl3/CH3OH: 2:1) in a rotavapor. After
overnight dessication, liposomes were prepared by 1-h
hydration of the dry lipidic film with Tris buffer pH 8 (Tris
10 mM, NaCl 150 mM, EDTA 0.1 mM, NaN3 1 mM) at 37
jC in a nitrogen atmosphere. The suspension was sonicated
at 4 jC under a stream of nitrogen with a Braun Labsonic-L
sonotrode (Braun Biotech International, Melsungen, Ger-
many) set at 50 W for 5 2 min with 1-min cooling
intervals until the opaque suspension became translucent.
The preparations were then centrifuged at 1000 rpm for 10
min (Damon IEC–CRU-5000) to remove particulate matter.
The actual phospholipid concentration of each preparation
was determined by phosphorus assay [36]. Total lipid
concentration was calculated assuming a similar recovery
of phospholipids and cholesterol. Liposomes were used the
day following their preparation.
2.2. Fluorescence and light scattering studies
2.2.1. Fusion of lipidic phase
The fusion of lipidic phases was determined by measuring
the dequenching of the fluorescence of octadecylrhodamine
B chloride (R18) [37]. The fluorescence of this lipid-soluble
probe is self-quenched in proportion with its membranous
concentration and any decrease of its surface density is
therefore associated with a commensurate increase of the
fluorescence intensity of the preparation [37]. Labeled lip-
osomes were obtained by incorporating R18 in the dry lipid
film at a molar ratio of 5.7%with respect to the total lipids and
diluted to a concentration of 5 AM in total lipids. These
labeled liposomes were mixed with unlabeled liposomes
(adjusted to the same concentration) at a ratio of 1:4. Peptide
(or piracetam) were added and the fluorescence was thereafter
followed at room temperature during 25 min, using kexc of
560 nm and kem of 590 nm (Perkin-Elmer LS-30, Perkin-
Elmer Ltd, Beaconsfield, UK). Additional experiments were
performed where liposomes were either preincubated 20 min
with piracetam before the addition of peptides or with
peptides during 20 min prior addition of the drug. Results
were expressed as fluorescence values calculated as the
difference between the fluorescence signal recorded for the
mixing of labeled and unlabeled liposomes and that recorded
in identical experimental conditions for the labeled liposomes
mixedwith peptide or piracetam. This correction was made to
rule out any interference of the peptide or piracetam on the
fluorescence of the marker.
2.2.2. Fusion of aqueous phase
Two preparations of labeled liposomes were used. The
first population of liposomes contained hydroxypyrene-
1,3,6-trisulfonic acid (HPTS; 1 mM) and the second p-
xylene-bis-pyridinium bromide (DPX; 50 mM) dissolved in
Tris buffer pH 8 (Tris 10 mM, NaCl 150 mM, EDTA 0.1
mM, NaN3 1 mM). The mixture of aqueous phases of the
two populations of liposomes was monitored by the
decrease of HPTS fluorescence due to the quenching of
HPTS fluorescence by DPX. After liposome preparations,
the unentrapped probes were eliminated by minicolumn
centrifugation. The two types of liposomes were diluted
with Tris buffer pH 8 at 50 AM and mixed at a ratio of 1:1.
Peptide (or piracetam) was added to the liposomes and the
fluorescence was thereafter followed at room temperature
during 25 min. In some experiments, liposomes were
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preincubated 20 min with piracetam before the addition of
peptide whereas in others, the drug was mixed to liposomes
preincubated 20 min with peptide. Fluorescence of HPTS
was monitored with a Perkin-Elmer LS30 fluorescence
spectrophotometer (Perkin-Elmer) using kexc of 450 nm
and kem of 512 nm.
2.2.3. Determination of the size of liposomes
The apparent average diameter of SUV was determined
by quasi-elastic light scattering spectroscopy [38] using a
CoulterR Nano Sizerk N4MD (Coulter Electronics Ltd,
Luton, UK), as described earlier [39]. The liposomes con-
centration was set at 65 AM (total lipids).
Fluctuation of light scattering was measured at an angle
of 90j with monodisperse latex particles of 100- and 800-
nm diameters as control. Data were analyzed using size
distribution analysis mode to determine the full size distri-
bution profile of liposomes mixed with the h-amyloid
peptide and/or piracetam. In some experiments, liposomes
were preincubated 20 min with piracetam before the addi-
tion of peptide whereas in others the drug was mixed after
incubation during 20 min of liposomes with peptide.
2.2.4. Permeability studies
As described by Weinstein et al. [40], leakage of entrap-
ped, self-quenched calcein from liposomes can be moni-
tored by the fluorescence increase subsequent to its dilution.
The dried lipid films were hydrated with a solution of
purified calcein (16.3 mM) which had an osmolarity of
461 mOsm/kg [measured by the freezing point technique
(Advanced Instruments, Needham Heights, MA)]. After
preparation of the vesicles, the unencapsulated dye was
eliminated by the minicolumn centrifugation technique
[41]. The liposomes were diluted to a final lipid concen-
tration of 5 AM in an isoosmotic 231 mM Tris buffer pH 8
(461 mOsm/kg), and then the peptide (or piracetam) was
added at room temperature. Again, additional experiments
were performed with liposomes preincubated 20 min with
piracetam (or peptide) before the addition of peptide (or
piracetam). The percentage of calcein released under the
influence of peptide was defined as [(FtFcontr)/(Ftot
Fcontr)] 100, where Ft is the fluorescence signal measured
at time t in the presence of the peptide, Fcontr is the fluo-
rescence signal measured at the same time t for control lipo-
somes, and Ftot is the total fluorescence signal obtained after
complete disruption of the liposomes by sonication (checked
by quasi-elastic light spectroscopy). All fluorescence deter-
minations were performed at room temperature on a Perkin
Elmer LS 30 Fluorescence Spectrophotometer (Perkin-El-
mer) using kexc of 472 nm and kem of 516 nm.
2.3. NMR studies
2.3.1. 31P NMR
Multilamellar vesicles (MLV) of the same composition as
that used for fluorescence and light scattering studies were
prepared as follows: organic solutions of the lipids were
dried under vacuum, hydrated over 1 h at 37 jC in Tris
buffer pH 8 at a concentration of 10 mM in phospholipids,
maintained at 37 jC for a further hour and finally submitted
to five freeze–thawing cycles. The same procedure was
used for preparing DMPC/DHPC (dimyristoylphosphatidyl-
choline/dihexanoylphosphatidycholine in a molar ratio of
3:2) liposomes at a concentration of 20 mM in phospholi-
pids.
Peptide-containing samples were prepared by the follow-
ing procedure: peptides were first dissolved in trifluoro-
acetic acid [42], the solvent removed with N2 gas and the
sample dried under vacuum. The peptide dissolved in
DMSO (6 mg/ml) was simply added to the MLV suspen-
sion. Piracetam-containing samples were obtained by dis-
solving in the buffer the necessary amount of drug to reach a
200 mM final concentration in the sample.
31P NMR spectra were obtained at 101.3 MHz with an
AC 250 Bruker spectrometer. Two milliliters of MLV
suspension were used in 10-mm NMR tubes. D2O (15%)
was added for locking on the deuterium signal. Fourier
transform conditions were: 25 kHz spectral width, 4 K data
points, flip angle 40j (10 As), 1.2 s pulse interval. Five
thousand scans were accumulated and a 50-Hz line broad-
ening was applied to the free induction decay before Fourier
transformation. Powergated 1H decoupling was applied.
Experiments were conducted as a function of temperature:
samples were heated and cooled down with 30-min equili-
bration times between each accumulation at each new
temperature.
2.3.2. 2H NMR
Aqueous solution of binary mixtures of long- and short-
chain phosphatidylcholines may form a well-oriented nem-
atic phase of bilayered discoidal mixed micelles called
bicelles [43]. We used DMPC/DHPC in a molar ratio of
3.5:1. The DMPC solution in CHCl3 (containing 25% of
DMPC-d54) was evaporated under vacuum, resuspended in
2H-depleted water and vortexed, centrifuged and freeze–
thawed for obtaining a homogeneous slurry. Stock solution
of DHPC in 2H-depleted water was added to the DMPC
suspension. The final phospholipid content of 20% (w/w)
was adjusted with 50 mM 2-morpholinoethane sulfonic acid
monohydrate (MES) pH 6.
Peptide-containing samples were prepared by the same
procedure as for 31P NMR studies but the Ah 29–42 in
DMSO (see supra) was added to a CHCl3 solution of
DMPC. The solvents were evaporated under vacuum, the
dry peptide–DMPC mixture was resuspended in 2H-
depleted water and this suspension was treated as control
samples (see above) before addition of DHPC solution and
buffer. During this study, severe difficulties appeared in
the bicelle preparation: the samples were highly viscous
but not completely transparent. After centrifugation, the
suspension became more transparent but a pellet was
observed, indicating that the peptide was not well inserted
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in the bicelles. For improving this incorporation, we
decided to perform the 2H NMR study with a less
hydrophobic fragment of Ah, the 22–42 peptide. This
fragment, which also induces significant lipid fusion [20],
is much less hydrophobic than the Ah 29–42 as indicated
by the calculated grand average of hydrophobicity
(GRAVY index; [44]) (1.07 vs. 2.41) or by the normalised
consensus hydrophobicity scale of Eisenberg et al. [45]
(0.47 vs. 0.89). We decided to synthesise this fragment
with a Tyr residue at the N-terminus (GRAVY index of
0.96) to allow the peptide purification by HPLC.
The incorporation of Tyr-22–42 in bicelle solutions was
satisfactory. The longer peptide-containing samples were
transparent and highly viscous after addition in DHPC
solution.
The preparation of piracetam-containing samples was
similar to that of control bicelles, but the drug was dissolved
in the 2H-depleted water employed for resuspending DMPC
or DMPC–peptide mixture.
NMR samples of 200 Al were introduced in short 5-mm
tubes and sealed tightly. Before data acquisition, the sam-
ples were kept a 37 jC for 1 h, for allowing equilibrium
alignment to be established. Deuterium NMR spectra were
recorded at 55.3 MHz on a Chemagnetics CMX 250/360
spectrometer. The standard quadruple echo sequence [46]
with s = 50 As, 90j pulse of 2.1 As and a repetition time of
1.2 s was used. Four thousand scans were accumulated; 4 K
data points were acquired, fractionally left-shifted to start
the record at the top of the echo, baseline-corrected and
zero-filled to 16 K. A line broadening of 100 Hz was
applied to the free induction decay prior to Fourier trans-
formation.
2.4. Computational methods
2.4.1. 3D construction of the molecules
3D structure of peptides, phospholipids and piracetam
was calculated as previously described [20,47–49]. The
methods account for the contribution of a lipid–water
interface by the concomitant variation of the dielectric
constant and the energy of transfer of atoms from a hydro-
phobic to a hydrophilic environment.
For the Ah Tyr-22–42 peptide, the conformation of the
22–28 segment was calculated using the stereoalphabet
procedure [50,51], with the 29–42 end considered as a-
helical. Briefly, in this procedure, six values of //w torsional
angles (/ and w values:  60, 40;  160, + 160;  140,
+ 80;  80, + 160;  80, + 80; + 60, + 60), representing
the most frequent angle pairs of the Ramachandran plot, are
combined to find the most stable conformation of the whole
Ah Tyr-22–42 peptide. 6n conformations of the peptide are
thus considered, with n = 7 (residues 22 to 28). The most
stable structure after energy minimisation is considered for
further calculations.
The molecules were then oriented at the hydrophobic/
hydrophilic interface taking into account the hydrophobic
and hydrophilic centres, calculated as described elsewhere
[47].
The molecular hydrophobicity potential (MHP) of pira-
cetam was determined as described by Brasseur [48].
2.4.2. Assembly of Ab Tyr-22–42 or Ab 29–42 with
phospholipids and piracetam
The procedure is derived from that used to surround
drugs with lipids [47]. In the hypermatrix procedure, the
lipid/water interface is taken into account by linearly vary-
ing the dielectric constant e between 3 (above the interface)
and 30 (below the interface).
In the calculations, we simulate the interaction of Ah
29–42 or Ah Tyr-22–42 with either dipalmitoylphosphati-
dylethanolamine (DPPE) molecules or with a lipid molecule
(DPPE) complexed to piracetam. This complex was
obtained as described previously [49].
The initial position and orientation of the molecules are
defined using the TAMMO procedure [47]. The position of
Ah 29–42 or AhTyr-22–42 is constant while the first lipid
molecule (or lipid/piracetam complex) translates towards
the peptide along the X axis by l steps of 0.05 nm. It rotates
by steps of 30j around its ZVaxis and around the X axis: l is
the number of positions tested along the X axis, m is the
number of rotations around the peptide and n is the number
of rotations around the lipid (or lipid/piracetam complex)
itself. For each set of l, m and n values, the energy of
interaction between Ah Tyr-22–42 (or Ah 29–42) and
lipid (or lipid/piracetam complex) is calculated as the sum
of van der Waals, electrostatic and hydrophobic terms.
Then, for each set of values l, m and n, the lipid (or
lipid/piracetam) molecule moves by step of 0.05 nm along
the ZVaxis perpendicular to the interface and the angle of ZV
axis bends F 5j with respect to the Z axis. The energy
values together with the coordinates of all assemblies are
stored in a matrix and classified according to decreasing
values. The most stable matching is used to decide the
position of the first lipid (or lipid/piracetam complex). The
position of the second lipid (or lipid/piracetam) is then
defined as the next most energetically favourable orienta-
tion stored in the hypermatrix taking sterical and energetic
constraints due to the presence of the first lipid molecule
(or lipid/piracetam) taken into account. To further minimise
the energy of the complex, the position of both lipid (or
lipid/piracetam) molecules is alternatively modified accord-
ing to the energy classification of the Hypermatrix. For the
next lipid molecule, the same process is repeated but the
positions of all surrounding molecules are modified alter-
natively in order to find the lowest energy state. In these
calculations, the energy of interaction between all lipids is
minimised. The process ends when Ah Tyr-22–42 or Ah
29–42 is completely surrounded with lipids (or lipid/
piracetam complexes).
All calculations are performed on Pentium III processors,
using the Z-TAMMO software. Graphs were drawn using
Win-MGM (Ab Initio technology, Obernai, France).
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2.5. Materials
Ah 29–42 peptide was synthesised by Polypeptides
laboratories (Wolfenbu¨ttel, Germany) and solubilised in
1,1,1,3,3,3-hexafluoro-2-propanol (HFP) except for NMR
measurements (cf. supra). The sequence of Ah 29–42 is
Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala.
The synthesis of Ah Tyr-22–42 fragment was performed
by using FMOC chemistry on a PerSeptive Biosystem
solid-state peptide synthesiser. The peptide was purified by
HPLC (Waters) and its identity and purity were confirmed
with mass spectrometry. Piracetam provided by UCB
Pharma (Brainel’Alleud, Belgium) was solubilized in Tris
buffer pH 8 or 2H-depleted water for NMR measurements
on bicelles. Egg yolk phosphatidylcholine, wheat germ
phosphatidylinositol and egg yolk phosphatidylethanol-
amine (grade 1) were purchased from Lipid Products (Nr
Redhill, UK). Sphingomyelin and cholesterol were
obtained from Sigma Chemical Co. (St. Louis, MO).
Bovine spinal cord phosphatidylserine was purchased from
Avanti Polar Lipids, Inc. (Birmingham, AL). Octadecylr-
hodamine B (R18), hydroxypyrene-1,3,6-trisulfonic acid
(HPTS) and p-xylene-bis-pyridinium bromide (DPX) were
obtained from Molecular Probes (Eugene, OR, USA).
Calcein, purchased from the Sigma Chemical Co., was
purified by chromatography on Sephadex LH-20 following
the technique of Lelkes [41], and the purity of the final
product was checked by TLC on silica gel G using
CH3OH/NH4OH 28% (9:1.5 v/v) as mobile phase. 1,2-
Dimyristoyl-n-glycero-3-phosphocholine (DMPC), deuter-
ated 1,2-di[myristoyl-d27]-n-glycero-3-phosphocholine
(DMPC-d54) and 1,2-dihexanoyl-n-glycero-3-phosphocho-
line (DHPC) were purchased from Avanti Polar Lipids
(Alabaster, AL) and deuterium [2H]-depleted water from
Cambridge Isotopes (Cambridge, MA). Other reagents
were obtained from E. Merck (Darmstadt, Germany) and
were of analytical grade.
3. Results
3.1. Fluorescence and light scattering studies
3.1.1. Fusion of lipidic phases
The measurement of fluorescence dequenching of octa-
decylrhodamine B (R18) is an established technique to study
the fast mixing of lipids occurring during fusion of adjacent
membranes [37].
Piracetam did not induce any significant dilution of
octadecylrhodamine B up to a piracetam/lipid molar ratio
of 9600 during an exposure time of 25 min, suggesting no
effect on mixture of lipidic phases (Fig. 1). In contrast, with
peptide Ah 29–42, a rapid and marked increase in fluo-
rescence was observed over the first few minutes followed
by a very slow increment, as already observed for other
fusion peptides [20,52] (Fig. 1). The effect of peptide Ah
29–42 was dose-dependent and was maximal for a peptide/
lipid molar ratio of 0.2.
This increase of fluorescence induced by peptide was
almost completely prevented when liposomes are preincu-
bated with piracetam (20 min), before the addition of
peptide (Fig. 1). This effect was concentration-dependent
(increasing piracetam/peptide molar ratios from 9.6 to 960)
and was not observed when piracetam was added after the
incubation of liposomes with peptide.
3.1.2. Fusion of aqueous phases
Fusion of liposome aqueous compartments can be moni-
tored by the decrease of HPTS fluorescence following the
mixture of HPTS and DPX contained in the aqueous
compartment of two separate liposome preparations.
Piracetam did not induce any significant decrease of
fluorescence (up to a piracetam/lipid ratio of 9600) during
an exposure time of 25 min (Fig. 2). In contrast, Ah 29–42
induces a fast decrease of fluorescence (t1/2 < 30 s) which
was peptide/lipid ratio-dependent (from a ratio of 0.3 to 3)
(Fig. 2). The maximum effect was obtained at a peptide/lipid
molar ratio of 3.
At this ratio, we investigated the effect of increasing
amounts of piracetam (piracetam to peptide molar ratios
from 9.6 to 960). Preincubation of piracetam, at a piracetam/
peptide ratio of 960, during 20 min before the addition of
peptide prevented almost completely the mixture of the two
fluorescent probes. Again, it is interesting to note the dose-
dependent effect and the fact that piracetam was not able to
reverse the effect of the Ah-amyloid fragment when peptide
was first incubated with liposomes (Fig. 2).
Fig. 1. Effect of piracetam and/or peptide Ah 29–42 on the fusion of lipidic
phases of liposomes. Liposomes (PC/PE/PI/PS/SM/Chol; 30%:30%:
2.5%:10%:5%:22.5%) are added at room temperature to Ah 29–42 (pep-
tide/lipid molar ratio = 0.2) (n) or piracetam (piracetam/lipids = 9600) (z).
Piracetam was also first preincubated with liposomes during 20 min before
addition of HFP or peptide at different piracetam/peptide ratios [(o)
piracetam/peptide molar ratio = 9.6; (5) piracetam/peptide molar ratio = 96;
(D) piracetam/peptide ratio = 960]. In additional experiments, piracetam
was added after incubation of liposomes with peptide during 20 min
(piracetam/peptide ratio = 960) (.). Each point is the mean value of three
independent experiments but the S.D. (< 5) are not shown for the sake of
clarity.
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3.1.3. Size of the liposomes
To further verify the ability of Ah 29–42 peptide and/or
piracetam to induce fusion of membranes, we investigated
their capacity to modify the apparent size and homogeneity
of the liposomes preparation by means of a light scattering
assay (Fig. 3).
Piracetam had no effect on the apparent size diameter of
liposomes since the size obtained was similar to that
observed for control liposomes. In contrast, at a peptide/
lipid molar ratio of 2, Ah 29–42 peptide caused a striking
increase in the apparent diameter of the particles and
induced the appearance of two populations (Fig. 3).
Again, preincubation of liposomes with piracetam before
the addition of peptide prevented the appearance of the two
populations induced by the addition of peptide. As for the
other experiments, no effect of piracetam was observed
when the peptide was incubated with liposomes before the
addition of the drug (Fig. 3).
3.1.4. Calcein permeability
Calcein is a polar molecule that has been widely used to
study the permeability of lipid bilayers and has been
originally described for this application by Weinstein et al.
[40].
The effect induced by Ah 29–42 peptide, piracetam or
both on membrane permeability is shown on Fig. 4. In
contrast to piracetam which did not induce any significant
leakage of entrapped calcein (up to a piracetam/lipid ratio
of 9600) during an exposure time of 25 min, Ah 29–42
peptide induced a fast ( < 60 s), dose-dependent and al-
most complete release of calcein from liposomes as
observed previously for mellitin [53], a known porogenic
agent [54]. The release was observed at peptide to lipid
ratios ranging from 0.3 to 12 and was maximal from a
ratio of 6.
At this peptide/lipid ratio, preincubation of piracetam
with lipids prevented almost completely the release of
calcein induced by the peptide in a dose-dependent fashion
(piracetam/peptide ratios from 9.6 to 960). Again, piracetam
was not able to reverse the effect of the Ah-amyloid frag-
ment when the peptide was incubated with liposomes prior
to the addition of piracetam (Fig. 4).
Fig. 3. Effect of piracetam and/or peptide Ah 29–42 on apparent mean
diameter of liposomes. Liposomes (PC/PE/PI/PS/SM/Chol; 30%:30%:
2.5%:10%:5%:22.5%) are mixed at room temperature with Ah 29–42
(peptide/lipid molar ratio = 2) or with piracetam (piracetam/lipid ratio =
19200). Piracetam was also first preincubated 20 min with liposomes before
addition of HFP or peptide or added after incubation during 20 min of
liposomes with peptide. The percentage of each population found is in-
dicated at the top of the histogram. Readings are given as meanF S.D.
Fig. 4. Effect of piracetam and/or peptide Ah 29–42 on the calcein
release from liposomes. Liposomes (PC/PE/PI/PS/SM/Chol; 30%:30%:
2.5%:10%:5%:22.5%) are added at room temperature to Ah 29–42
(peptide/lipid molar ratio = 6) (n) or piracetam (z) (piracetam/
lipids = 9600). Piracetam was also first preincubated 20 min with
liposomes before addition of HFP or peptide at different piracetam/
peptide ratios [(o) piracetam/peptide molar ratio = 9.6; (5) piracetam/
peptide molar ratio = 96; (D) piracetam/peptide ratio = 960]. In additional
experiments, piracetam was added after incubation during 20 min of
liposomes with peptide (piracetam/peptide ratio = 960) (.). Each point is
the mean value of three independent experiments but the S.D. (< 2.5%)
are not shown for the sake of clarity.
Fig. 2. Effect of piracetam and/or peptide Ah 29–42 on the fusion of
aqueous phases of liposomes. Liposomes (PC/PE/PI/PS/SM/Chol; 30%:
30%:2.5%:10%:5%:22.5%) are mixed at room temperature with Ah 29–42
(peptide/lipid molar ratio = 3) (n) or with piracetam (z) (piracetam/li-
pids = 9600). Piracetam was also first preincubated 20 min with liposomes
before addition of HFP or peptide at different piracetam/peptide ratios [(o)
piracetam/peptide molar ratio = 9.6; (5) piracetam/peptide molar ratio = 96;
(D) piracetam/peptide ratio = 960]. In additional experiments, piracetam
was added after incubation during 20 min of liposomes with peptide
(piracetam/peptide ratio = 960) (.). Each point is the mean value of three
independent experiments but the S.D. ( < 15) are not shown for the sake of
clarity.
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3.2. NMR studies
3.2.1. 31P NMR
Spectra were recorded for control liposomes and samples
containing either Ah 29–42 or piracetam and peptide. Ty-
pical spectra are shown on Fig. 5. Control liposomes (Fig.
5A) gave a broad spectrum characteristic of MLV with a
maximum at high field and a shoulder at low field. At pep-
tide/phospholipid ratio of 0.2, peptide-containing liposomes
spectra (Fig. 5B) revealed modifications of lipid organisation
depicted by a narrow signal that became very important at
65 jC. Addition of piracetam in liposome suspension (drug/
lipid ratio of 20) had no significant influence on the spectral
shapes (data not shown) but incubation of liposomes with
piracetam prior to the addition of the peptide to the sample
markedly reduced the peptide effect as illustrated by the
reduction of the narrow signal at 65 jC (Fig. 5C) compared
to what was observed for MLV incubated with peptide alone
(Fig. 5B). The Ah 29–42 peptide effect was irreversible
since adding piracetam to peptide-containing liposomes had
no influence on the development of the narrow signal
induced by the peptide (data not shown).
For comparing the effect of Ah 29–42 fragment with
that of peptide Ah Tyr-22–42 which was used in the 2H
NMR studies performed with DMPC/DHPC bicelles, 31P
NMR spectra of DMPC/DHPC (3:2 molar ratio) liposomes
were run without and with that longer peptide. Control
liposomes (Fig. 6A) revealed a small proportion of narrow
peak that increased when Tyr-22–42 peptide was added to
the liposomes (peptide/phospholipids ratio of 0.04) (Fig.
6B). Since after purification of Ah Tyr-22–42 fragment a
very limited amount of peptide was obtained, all the
available peptide was used for 2H NMR measurements on
bicelle samples.
3.2.2. 2H NMR
The 2H quadruple echo spectrum of DMPC-d54 in
bicelles was run for control sample (Fig. 7A). The deuteron
spectra are characteristic of macroscopically aligned phos-
pholipid bilayers oriented with their normal orthogonal to
the magnetic field direction [43]. The 90j components of
the 2H powder pattern are the only visible components for
this sample with a very high degree of orientation. The
separation between the outermost lines corresponds to the
quadrupolar splitting of the C2–C5 methylene groups of
DMPC (plateau region) while the central doublet is assigned
to the deuteron resonance of the DMPC terminal methyl
group [55].
The incorporation of piracetam in bicelle solution slightly
modified the 2H NMR spectrum of DMPC-d54 in bicelles. As
seen on spectra of Fig. 7B, the resolution of spectral com-
ponents is reduced compared to that observed for control
bicelles. The temperature effect between 35 and 40 jC was
negligibly small.
The incorporation of AhTyr-22–42 peptide in the bicelle
preparation had dramatic effects on the spectral shape (Fig.
7C). Already at 35 jC, the broadening of the spectral
components evidenced phospholipid structural perturbation.
By heating the sample up to 40 jC, a narrow peak became
prominent and this transformation became more pronounced
even after cooling the sample down to 35 jC.
Fig. 6. 31P NMR spectra at 25 jC of DMPC/DHPC (3:2 molar ratio)
multilamellar liposomes after a thermal cycle (heating from 25 to 45 jC and
cooling down to 25 jC). (A) Control liposomes; (B) After addition of Tyr-
22–42 fragment (peptide/phospholipids 0.04).
Fig. 5. 31P NMR spectra of multilamellar liposomes upon warming (35 and
65 jC). (A) Control liposomes (PC/PE/PI/PS/SM/Chol; 30%:30%:2.5%:
10%:5%:22.5%); (B) After addition of Ah 29–42 (peptide/phospholipids
0.2); (C) with preliminary addition of piracetam (200 mM) and subsequent
addition of Ah 29–42 peptide (peptide/phospholipids 0.2).
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In the presence of preliminary added drug and subse-
quent addition of Ah Tyr-22–42 fragment (Fig. 7D), the
major spectral modification at 35 jC induced by the peptide
was prevented. Raising and lowering temperature did not
appreciably modify the spectral line shape.
As observed by 31P NMR, when piracetam was added to
the peptide-containing bicellar sample, the spectrum evolu-
tion was similar to that observed on sample containing only
the peptide (data not shown). The transformations induced
by the peptide are irreversible.
3.3. Molecular modelling
The molecular structure of piracetam is presented on Fig.
8A; it was obtained as described elsewhere [49]. Molecular
Hydrophobicity Potentials (MHP) (Fig. 8B), based on
atomic transfer energies and calculated as described by
Brasseur [48], show clearly that piracetam is perfectly
amphipathic, one moiety being hydrophilic (green envelope)
and the other being hydrophobic (orange envelope). This
property is related to the ability of piracetam to coat the
phospholipid headgroups [49].
The interaction between the Ah Tyr-22–42 peptide and
DPPE molecules was calculated using the hypermatrix
procedure [47]. Fig. 9A shows clearly that the peptide
induces a destabilisation of the lipids by disturbing the
parallelism of the acyl chains. This is accompanied by the
appearance of a negative curvature at the lipid surface. As
already suggested for other tilted peptides [30], these
changes could be the first events leading to lipid fusion. In
contrast, when the same peptide interacts with DPPE in the
Fig. 8. (A) CPK (Corey-Pauling-Kaltum) representation of piracetam. Color
of atoms is as follows: grey:carbon; blue:nitrogen; red:oxygen; white:-
hydrogen; (B) MHP surfaces (calculated as described by Brasseur [48])
around piracetam in the same orientation as in (A). Green surface represents
the hydrophilic domain, and the orange surface the hydrophobic one. The
surfaces are cut by a plane to visualize the molecule.
Fig. 7. 2H NMR spectra of DMPC-d54 in DMPC/DHPC (3.5:1) bicelle solution at 35 and 40 jC and after cooling down at 35 jC. (A) Control bicelles; (B)
Piracetam (200 mM) containing DMPC/DHPC bicelle solution; (C) Tyr-22–42 peptide containing bicelles (peptide/phospholipids 0.04); (D) Piracetam (200
mM) containing DMPC/DHPC bicelle solution submitted to the Tyr-22–42 peptide action (peptide/phospholipids 0.04).
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presence of piracetam, these effects are lost, i.e. no pertur-
bation of the acyl chain organisation can be observed, as well
as no change in the lipid curvature (Fig. 9B). The same was
observed when calculating the interaction of Ah 29–42 with
DPPE and DPPE/piracetam complexes (data not shown).
4. Discussion
The development of new therapeutic approaches to the
treatment of cognitive disorders is a real and urgent problem
due to demographic changes and the strong increase in mean
life expectancy in developed countries. Among the possible
therapeutic interventions, 2-pyrrolidone derivatives [56]
such as piracetam are currently used in some countries.
This nootropic agent for which no metabolite has been
found [57] is known to enhance the oxidative glycolysis,
to increase acetylcholine release and synthesis of cyto-
chrome h5 [58], to improve red blood cell deformability
in vitro and to restore impaired deformability of physiolog-
ically deoxygenated sickled red cells [59]. In addition,
recent interest has focused on the neuroprotective effects
of piracetam, for instance, in the aftermath of acute stroke
[60] and on its antimyoclonic action [61]. The molecular
basis of piracetam beneficial effects in Alzheimer’s disease
is, however, unknown.
By using biophysical techniques, NMR spectroscopy and
conformational analysis, the present study was aimed at
investigating the effect of piracetam on the lipid-destabilis-
ing activity induced by Ah fragments. The in vivo relevance
of the experimental model employed in the current work has
been ascertained by literature data. With respect to peptides,
most of our experiments were carried out with Ah 29–42 at
peptide concentrations varying from 1 to 50 AM. Under
normal conditions the physiological concentration of Ah in
the cerebrospinal fluid is around 0.5 nM [62,63] but by
aging or under pathological situations, the degradation path-
way of Ah via the low density lipoprotein receptor-related
protein or via a scavenger receptor is reduced byf 45%
[64], which would increase the extracellular content of Ah.
Moreover, since biological membranes are heterogeneous,
locally high peptide concentrations can be obtained transi-
ently and, thus, the peptide concentrations used could be
similar to those found under in vivo conditions. Likewise,
the maximum effect of piracetam was observed for drug
concentrations compatible with those used in clinics (pira-
cetam/peptide ratio of f 1000 implying a piracetam con-
centration of 10 mM; [65]).
One of the most characteristic neuropathological signs of
Alzheimer’s disease is the deposition of neuritic plaques
composed of Ah proteins, 39–42 amino acids long, and
derived from the transmembrane region of the APP [66].
Conformational analysis of the Ah protein showed that its C-
terminal domain (e.g. amino acids 29–40 or 29–42) has
properties similar to those of the fusion peptide of viral
proteins [67], i.e. a tilted penetration into membranes
[48,52]. This oblique insertion is thought to be responsible
for disturbance of the acyl chain parallelism, curvature of the
membrane surface and, consequently, membrane destabilisa-
tion. As previously shown [20,68], Ah 29–42 or its less
hydrophobic analog Ah 22–42 is able to induce membrane
fusion and permeabilisation of lipid vesicles mimicking the
composition of neuronal membranes [35]. We have shown
here that the fusogenic effect is related to the appearance of
non-bilayer structures where isotropic motion occurs, as
measured by 31P NMR studies, an observation which was
previously related to fusogenic properties of other peptides
[69–72]. As observed by 2H NMR, the Ah Tyr-22–42
fragment effect on bicelles [73,74] is quite comparable to
the 29–42 fragment perturbing effect. Ah Tyr-22–42 disor-
ganises the bilayer structure as seen on the spectra by the
transformation of the broad signal into a relatively narrow
peak. Molecular modelling calculations support these exper-
imental observations and suggest that lipid destabilisation
could be due to the ability of tilted peptides to adopt
metastable positions in the presence of lipids [75].
Fig. 9. (A) interaction between the Ah Tyr-22–42 peptide (green CPK representation) and DPPE lipid molecules. Assembly is calculated as described in
Section 2. The yellow lines indicate the tilt of the acyl chains induced by the peptide. The dashed yellow curve indicates the effect on the lipid curvature; (B)
same as in (A) for the interaction between the Ah Tyr-22–42 peptide, DPPE and piracetam.
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According to several observations, emerging hypotheses
to explain the benefit of piracetam in Alzheimer’s disease
may involve lipids. First, piracetam is an amphiphilic drug
and several molecules of piracetam simultaneously interact
with one phospholipid molecule, as shown by molecular
modeling. In the case of DPPE, we can consider that more
than 80% of the water molecules in contact with the
phospholipid polar heads have been replaced by piracetam,
thus modifying the physical properties of the phospholipids
[24,49]. Second, using a two-hybrid system as described by
Hughes et al. [76] and Festy et al. [77], we showed no effect
of piracetam on the interaction properties of the entire Ah
protein. Third, in 1H NMR, the proton chemical shifts of the
drug mixed with Ah 29–42 (2:1) obtained in organic
solution did not reveal any significant modifications com-
pared to the shifts of the drug alone in DMSO solution.
Investigating further the effect of piracetam on mem-
brane fusion or permeability induced by Ah peptide, we
have shown that piracetam is able to significantly decrease
the fusogenic and destabilising effect of Ah 29–42, in a
concentration-dependent manner. It is worth noting that the
same is observed for Ah 29–40 and Ah 22–42. This is in
agreement with the 31P and 2H NMR results since the
phospholipid bilayer disorganisation induced by the two
fragments and shown by the development of a narrow peak
is substantially reduced in piracetam containing samples.
This may be interpreted as a stabilisation of the bilayer
structures that inhibits their transformation into isotropic
structures responsible for the observed narrow signals as it
was observed for inhibitors of viral fusion (lipogastrins
[78]). This effect only occurs when the drug is incubated
with liposomes prior to peptide addition. Adding piracetam
to liposomes preincubated with peptide does not reverse the
effect of the peptide on the lipids, suggesting that the lipid
destabilising process induced by the peptide is irreversible.
According to our observations and data reported in the
literature, the benefit of piracetam in Alzheimer’s disease
may thus result from interactions with lipids. Two main
hypotheses could explain the potential inhibitory effect of
piracetam on membrane destabilisation induced by Ah 29–
42. First, piracetam could make the membrane interfaces
more polar and hydrated [79] and it is well known that
strongly hydrated lipids such as phosphatidylcholine inhibit
the fusion of viral membranes with negatively-charged
liposomes [80,81]. Conversely, less hydrated lipids such
as phosphatidylethanolamine sustain membrane destabilisa-
tion. Second, inhibition of fusion could also result from
expanding the headgroup area of the outer monolayer so as
to produce positive curvature strain, a process which locally
curves the cell membrane in a direction opposite to that
induced by the fusogenic peptide [82].
While the peptide induces lipid disorganisation and
negative curvature of the membrane interface, conforma-
tional analysis showed that piracetam, when preincubated
with lipids, coats the phospholipid headgroups. Calculations
suggest that this prevents the appearance of curvature. This
is especially pronounced for phosphatidylethanolamine.
Additionally, insertion of molecules with an inverted cone
shape, such as piracetam, into the outer leaflet of one or both
membranes makes the formation of these structures ener-
getically less favourable and therefore decreases the like-
lihood of membrane fusion. In such a manner piracetam
may hinder the permeabilising effect of Ah-peptide.
Taken together, our data indicate that piracetam inhibits
the lipid-destabilising effect of the amyloid peptide, but
additional knowledge on this protective effect is required to
fully develop the therapeutic potential of 2-pyrrolidone
derivatives.
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